BACE1 and early-onset autosomal dominant Alzheimer disease: Third, it is still uncertain and remains a matter of ongoing research as to when the administration of BACE1 inhibitors will provide optimal results, with more recent results indicating a more prophylactic benefit at early stages of Alzheimer’s disease [44].